PL3065759T3 - Środki immunosupresyjne i ich zastosowanie w leczeniu - Google Patents
Środki immunosupresyjne i ich zastosowanie w leczeniuInfo
- Publication number
- PL3065759T3 PL3065759T3 PL14793594T PL14793594T PL3065759T3 PL 3065759 T3 PL3065759 T3 PL 3065759T3 PL 14793594 T PL14793594 T PL 14793594T PL 14793594 T PL14793594 T PL 14793594T PL 3065759 T3 PL3065759 T3 PL 3065759T3
- Authority
- PL
- Poland
- Prior art keywords
- therapy
- immunosuppressive agents
- immunosuppressive
- agents
- Prior art date
Links
- 229940125721 immunosuppressive agent Drugs 0.000 title 1
- 239000003018 immunosuppressive agent Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1319620.9A GB201319620D0 (en) | 2013-11-06 | 2013-11-06 | Immunosuppressive agents and their use in therapy |
| PCT/EP2014/073966 WO2015067712A1 (en) | 2013-11-06 | 2014-11-06 | Immunosuppressive agents and their use in therapy |
| EP14793594.4A EP3065759B1 (en) | 2013-11-06 | 2014-11-06 | Immunosuppressive agents and their use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3065759T3 true PL3065759T3 (pl) | 2021-10-25 |
Family
ID=49767770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14793594T PL3065759T3 (pl) | 2013-11-06 | 2014-11-06 | Środki immunosupresyjne i ich zastosowanie w leczeniu |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10517923B2 (pl) |
| EP (1) | EP3065759B1 (pl) |
| DK (1) | DK3065759T3 (pl) |
| ES (1) | ES2869901T3 (pl) |
| GB (1) | GB201319620D0 (pl) |
| HR (1) | HRP20210792T1 (pl) |
| LT (1) | LT3065759T (pl) |
| PL (1) | PL3065759T3 (pl) |
| PT (1) | PT3065759T (pl) |
| RS (1) | RS62047B1 (pl) |
| WO (1) | WO2015067712A1 (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12060396B2 (en) | 2013-04-11 | 2024-08-13 | Vanderbilt University | Fused in sarcoma (FUS) nuclear translocation inhibitors for preventing fibrosis |
| GB201319621D0 (en) * | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Antimicrobial agents and their use in therapy |
| GB201319620D0 (en) * | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Immunosuppressive agents and their use in therapy |
| GB201507721D0 (en) * | 2015-05-06 | 2015-06-17 | Norwegian Univ Sci & Tech Ntnu | Immunosuppressive agents and their use in therapy |
| GB201507722D0 (en) | 2015-05-06 | 2015-06-17 | Norwegian Univ Sci & Tech Ntnu | Anti-bacterial agents and their use in therapy |
| WO2017165452A1 (en) * | 2016-03-21 | 2017-09-28 | Rhode Island Council On Postsecondary Education | pH-SENSITIVE PEPTIDES |
| MX2020014330A (es) * | 2018-12-26 | 2021-03-09 | Caregen Co Ltd | Composicion para relajacion muscular. |
| WO2020138674A1 (ko) * | 2018-12-26 | 2020-07-02 | (주)케어젠 | 근육 이완용 조성물 |
| KR102469721B1 (ko) * | 2020-06-12 | 2022-11-23 | (주)케어젠 | 보툴리눔 톡신 유사 활성을 갖는 펩타이드 및 이의 용도 |
| KR102483938B1 (ko) * | 2020-06-12 | 2023-01-04 | (주)케어젠 | 펜타펩타이드를 유효성분으로 포함하는 항알러지 또는 아토피피부염 개선용 조성물 |
| CN115916236B (zh) * | 2020-06-12 | 2025-08-15 | 凯尔格恩有限公司 | 包含五肽作为活性成分的组合物 |
| KR102456989B1 (ko) * | 2020-06-12 | 2022-10-21 | (주)케어젠 | 항비만 활성을 가지는 디옥시콜산-펩타이드 결합체 및 이의 용도 |
| KR102463320B1 (ko) * | 2020-06-12 | 2022-11-07 | (주)케어젠 | 펜타펩타이드를 유효성분으로 포함하는 통증의 완화, 예방 또는 치료용 조성물 |
| KR102570768B1 (ko) * | 2020-06-12 | 2023-08-28 | (주)케어젠 | 펜타펩타이드를 유효성분으로 포함하는 다한증 치료용 조성물 |
| US11741686B2 (en) | 2020-12-01 | 2023-08-29 | Raytheon Company | System and method for processing facility image data |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198541A (en) | 1987-08-11 | 1993-03-30 | New York University | Dna encoding bactericidal/permeability-increasing proteins |
| US6316003B1 (en) * | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| CA2276548C (en) | 1992-05-19 | 2001-07-31 | Xoma Corporation | Improved methods for the preparation of endotoxin-binding proteins |
| US5420019A (en) | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
| PT690720E (pt) | 1993-03-12 | 2001-12-28 | Xoma Technology Ltd | Utilizacoes terapeuticas de produtos de proteina bactericida indutora de permeabilidade |
| JP4139863B2 (ja) | 1993-03-12 | 2008-08-27 | ゾーマ テクノロジー リミテッド | 殺菌性／透過性が向上したタンパク質の機能領域に由来する生物学的に活性なペプチドおよびその使用 |
| AU7970894A (en) | 1993-10-15 | 1995-05-04 | Xoma Corporation | Method of treating depressed reticuloendothelial system function |
| DE69527195T2 (de) | 1994-01-14 | 2003-03-06 | Xoma Technology Ltd., Berkeley | Anti gram positive bakterielle verfahren und mittel |
| AU703211B2 (en) | 1994-01-14 | 1999-03-18 | Xoma Corporation | Anti-fungal methods and materials |
| US5643875A (en) | 1994-01-24 | 1997-07-01 | Friedmann; Nadav | Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products |
| US5447913A (en) | 1994-03-11 | 1995-09-05 | Xoma Corporation | Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
| US5578568A (en) | 1994-04-22 | 1996-11-26 | Xoma Corporation | Method of treating conditions associated with intestinal ischemia/reperfusion |
| US5646114A (en) | 1994-07-11 | 1997-07-08 | Xoma Corporation | Anti-protozoan methods |
| WO1996008509A1 (en) | 1994-09-15 | 1996-03-21 | Xoma Corporation | Anti-fungal peptides |
| US5912228A (en) | 1995-01-13 | 1999-06-15 | Xoma Corporation | Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products |
| US5494896A (en) | 1995-03-31 | 1996-02-27 | Xoma Corporation | Method of treating conditions associated with burn injuries |
| US6057291A (en) * | 1995-06-02 | 2000-05-02 | University Of British Columbia | Antimicrobial cationic peptides |
| WO1997004008A1 (en) | 1995-07-20 | 1997-02-06 | Xoma Corporation | Anti-fungal peptides |
| US5686414A (en) | 1995-11-14 | 1997-11-11 | Xoma Corporation | Methods of treating conditions associated with corneal transplantation |
| US5851802A (en) | 1996-03-22 | 1998-12-22 | Xoma Corporation | Methods for recombinant microbial production of fusion proteins and BPI-derived peptides |
| US5741779A (en) | 1996-05-10 | 1998-04-21 | Xoma Corporation | Antithrombotic materials and methods |
| CA2253837C (en) | 1996-05-10 | 2002-07-02 | Xoma Corporation | Therapeutic uses of bpi protein products for human meningococcemia |
| ATE234111T1 (de) | 1996-05-23 | 2003-03-15 | Xoma Technology Ltd | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung |
| US5888973A (en) | 1996-08-09 | 1999-03-30 | Xoma Corporation | Anti-chlamydial uses of BPI protein products |
| US6482796B2 (en) | 1996-11-01 | 2002-11-19 | Xoma Corporation | Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients |
| WO1998019694A1 (en) | 1996-11-01 | 1998-05-14 | Xoma Corporation | Therapeutic uses of bpi protein products in cystic fibrosis patients |
| US6093573A (en) | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
| US6013631A (en) | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
| SE512161C2 (sv) | 1998-06-30 | 2000-02-07 | Sandvik Ab | Hårdmetall och användning av denna vid olje- och gasutvinning |
| AU6163099A (en) | 1998-09-25 | 2000-04-17 | Xoma Technology Ltd. | Antifungal and antibacterial peptide |
| EP1143996B1 (en) | 1999-01-22 | 2003-05-07 | XOMA Technology Ltd. | Use of a bpi protein for the preparation of a medicament for treating chronic cardiac disease |
| US6153584A (en) | 1999-04-01 | 2000-11-28 | Levy; Ofer | Therapeutic uses of BPI protein products in BPI-deficient humans |
| US6355616B1 (en) | 1999-06-25 | 2002-03-12 | Xoma (Us) Technology Ltd. | Derivative compounds derived from or based on bactericidal/permeability-increasing protein |
| US6376211B1 (en) | 1999-07-12 | 2002-04-23 | Xoma Technology Ltd. | Agents and methods for inhibiting F1/F0 ATPase |
| CA2379118A1 (en) | 1999-07-12 | 2001-01-18 | Xoma Technology Ltd. | Method to identify antimicrobial agents |
| WO2001004348A1 (en) | 1999-07-12 | 2001-01-18 | Xoma Technology Ltd. | Methods to identify inhibitors of f1/f0 atpase |
| AU4204200A (en) | 1999-07-12 | 2001-01-30 | Xoma Technology Ltd. | Therapeutic uses of bpi protein products for inhibiting H+/K+ atpase activity |
| US6777439B2 (en) * | 2000-05-30 | 2004-08-17 | Advanced Research & Technology Institute, Inc. | Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways |
| AU2002211885A1 (en) | 2000-10-11 | 2002-04-22 | Xoma Technology Ltd. | Antifungal peptides |
| EP1339424A2 (en) | 2000-12-01 | 2003-09-03 | XOMA Technology Ltd. | Modulation of pericyte proliferation using bpi protein products or bpi inhibitors |
| JP4310107B2 (ja) | 2001-03-28 | 2009-08-05 | ヘリックス バイオメディックス，インコーポレイテッド | 生物活性を有する短ペプチド及び該ペプチドの使用方法 |
| US7517857B2 (en) | 2002-01-29 | 2009-04-14 | Posco | Immune-modulating peptide |
| JPWO2005068504A1 (ja) * | 2004-01-19 | 2008-01-10 | 株式会社医学生物学研究所 | 炎症性サイトカイン抑制剤 |
| PT1928454E (pt) * | 2005-05-10 | 2014-12-04 | Intermune Inc | Derivativos da piridona para modulação do sistema de proteína quinase ativada pelo stress |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US7579318B2 (en) * | 2005-12-06 | 2009-08-25 | Centre De La Recherche De La Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| EP2084527A4 (en) * | 2006-11-02 | 2011-07-27 | Seattle Genetics Inc | METHOD FOR TREATING NEOPLASIA, AUTOIMMUNE AND INFLAMMATORY DISEASES |
| US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
| GB0803352D0 (en) * | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
| WO2010055500A1 (en) * | 2008-11-17 | 2010-05-20 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | A vaccinia virus protein a46 peptide and use thereof |
| GB0916576D0 (en) * | 2009-09-22 | 2009-10-28 | Malmsten Nils M | Polypeptides and uses thereof |
| WO2011043740A1 (en) * | 2009-10-09 | 2011-04-14 | Kemijski Institut | Peptides for inhibition of myd88-dependent signaling pathways |
| EP2538959A1 (en) * | 2010-02-24 | 2013-01-02 | Institut National de la Santé et de la Recherche Médicale | Compounds for the treatment of inflammation and neutropenia |
| US8697627B2 (en) * | 2011-05-09 | 2014-04-15 | Eip Pharma, Llc | Compositions and methods for treating alzheimer's disease |
| WO2012177892A2 (en) * | 2011-06-21 | 2012-12-27 | University Of Florida Research Foundation, Inc. | Type i interferon mimetics as therapeutics for cancer, viral infections, and multiple sclerosis |
| CA2878701C (en) * | 2011-07-12 | 2022-05-17 | The University Of British Columbia | Neuroprotective pepties that inhbit interaction between palmitoyl acyl transferase zinc-finger dhhc type containing 17 (zd17) and c-jun n-terminal kinase (jnk) |
| US9234048B2 (en) * | 2012-01-18 | 2016-01-12 | Wisconsin Alumni Research Foundation | Boronate-mediated delivery of molecules into cells |
| KR101497972B1 (ko) * | 2012-03-21 | 2015-03-03 | 서울대학교산학협력단 | Ｎｏｄ2 신호전달 경로를 표적으로 하는 패혈증 치료제 스크리닝 방법 및 패혈증 치료제 |
| GB201319620D0 (en) * | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Immunosuppressive agents and their use in therapy |
| GB201319621D0 (en) * | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Antimicrobial agents and their use in therapy |
-
2013
- 2013-11-06 GB GBGB1319620.9A patent/GB201319620D0/en not_active Ceased
-
2014
- 2014-11-06 US US15/034,917 patent/US10517923B2/en active Active
- 2014-11-06 HR HRP20210792TT patent/HRP20210792T1/hr unknown
- 2014-11-06 LT LTEP14793594.4T patent/LT3065759T/lt unknown
- 2014-11-06 RS RS20210577A patent/RS62047B1/sr unknown
- 2014-11-06 DK DK14793594.4T patent/DK3065759T3/da active
- 2014-11-06 PL PL14793594T patent/PL3065759T3/pl unknown
- 2014-11-06 PT PT147935944T patent/PT3065759T/pt unknown
- 2014-11-06 EP EP14793594.4A patent/EP3065759B1/en active Active
- 2014-11-06 WO PCT/EP2014/073966 patent/WO2015067712A1/en not_active Ceased
- 2014-11-06 ES ES14793594T patent/ES2869901T3/es active Active
-
2019
- 2019-11-13 US US16/683,188 patent/US11246907B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015067712A1 (en) | 2015-05-14 |
| GB201319620D0 (en) | 2013-12-18 |
| RS62047B1 (sr) | 2021-07-30 |
| US20160279193A1 (en) | 2016-09-29 |
| US20200323953A1 (en) | 2020-10-15 |
| LT3065759T (lt) | 2021-08-10 |
| US10517923B2 (en) | 2019-12-31 |
| DK3065759T3 (da) | 2021-05-17 |
| ES2869901T3 (es) | 2021-10-26 |
| PT3065759T (pt) | 2021-05-17 |
| EP3065759A1 (en) | 2016-09-14 |
| US11246907B2 (en) | 2022-02-15 |
| EP3065759B1 (en) | 2021-03-31 |
| HRP20210792T1 (hr) | 2021-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3065759T3 (pl) | Środki immunosupresyjne i ich zastosowanie w leczeniu | |
| GB201319621D0 (en) | Antimicrobial agents and their use in therapy | |
| HUE059544T2 (hu) | Polimixin-származékok és ezek alkalmazása kombinációs terápiában különbözõ antibiotikumokkal | |
| IL246221A0 (en) | Endazoles and their uses | |
| ZA201504902B (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
| IL242610A0 (en) | History of pyrazolopyrrolidine and their use in the treatment of diseases | |
| IL240248A0 (en) | Met-binding substances and their uses | |
| IL239904A0 (en) | Inhibitory oligonucleotides and their use in therapy | |
| GB201507721D0 (en) | Immunosuppressive agents and their use in therapy | |
| GB2515865B (en) | Use of galactooligosaccharides in therapy | |
| IL245597A0 (en) | Anti-neuroinflammatory and protective compounds in Achillea fragrantissima - implications for inflammatory and neurodegenerative diseases | |
| GB201507723D0 (en) | Anti-bacterial agents and their use in therapy | |
| GB201507722D0 (en) | Anti-bacterial agents and their use in therapy | |
| GB201310921D0 (en) | Peptide-resin conjugate and use thereof | |
| GB201305940D0 (en) | Methods and arrays for use in the same | |
| SG11201510468TA (en) | Compositions and methods for use in oncology | |
| GB201308753D0 (en) | Compounds and their use in therapy | |
| GB201304038D0 (en) | Treated cells and therapeutic uses | |
| IL243091B (en) | Compositions and methods for use in oncology | |
| GB201308217D0 (en) | Compounds and their use in therapy | |
| PL2857023T3 (pl) | Zastosowanie odiparcilu w leczeniu mukopolisacharydozy | |
| GB201319273D0 (en) | Improvements in structural members and methods relating thereto | |
| GB201322869D0 (en) | Therapeutic agents and delivery with microspheres | |
| GB201312129D0 (en) | Drug combination and its use in therapy | |
| GB201312128D0 (en) | Drug combination and its use in therapy |